Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: A first-in-man study

The Lancet

Volumn 378, Issue 9792, 2011, Pages 667-675

  Teerlink, John R ^a   Clarke, Cyril P ^b   Saikali, Khalil G ^c   Lee, Jacqueline H ^c   Chen, Michael M ^c   Escandon, Rafael D ^c   Elliott, Lyndsey ^d   Bee, Rachel ^d   Habibzadeh, Mohammad Reza ^a   Goldman, Jonathan H ^d   Schiller, Nelson B ^a   Malik, Fady I ^c   Wolff, Andrew A ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c Cytokinetics Inc   (United States)

^d ICON Medical Imaging   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OMECAMTIV MECARBIL; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CATHETER COMPLICATION; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SCREENING; DRUG TOLERABILITY; DYSGEUSIA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FATIGUE; FEMALE; HEART EJECTION FRACTION; HEART FUNCTION; HEART PALPITATION; HEART STROKE VOLUME; HUMAN; INJECTION SITE EXTRAVASATION; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SORE THROAT; THORAX PAIN;

EID: 80051967502     PISSN: 0140-6736     EISSN: 1474-547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)61219-1     Document Type: Article

References (23)

1. M Packer The search for the ideal positive inotropic agent N Engl J Med 329 1993 201 202 (Pubitemid 23195742)
2. D Lloyd-Jones, RJ Adams, TM Brown et al. Executive summary: heart disease and stroke statistics-2010 update: a report from the American Heart Association Circulation 121 2010 948 954
3. K Dickstein, A Cohen-Solal, G Filippatos et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM) Eur Heart J 29 2008 2388 2442
4. JR Teerlink, M Metra, V Zaca et al. Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond Heart Fail Rev 14 2009 243 253
5. G Hasenfuss, JR Teerlink Cardiac inotropes: current agents and future directions Eur Heart J 2011 10.1093/eurheartj/ehr026 published online March 8.
6. GM Felker, RL Benza, AB Chandler et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study J Am Coll Cardiol 41 2003 997 1003 (Pubitemid 36315544)
7. JN Cohn, SO Goldstein, BH Greenberg et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators N Engl J Med 339 1998 1810 1816 (Pubitemid 29005785)
8. JG Cleland, N Freemantle, AP Coletta, AL Clark Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE Eur J Heart Fail 8 2006 105 110 (Pubitemid 43012109)
9. A Mebazaa, MS Nieminen, M Packer et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial JAMA 297 2007 1883 1891 (Pubitemid 46707842)
10. JR Teerlink A novel approach to improve cardiac performance: cardiac myosin activators Heart Fail Rev 14 2009 289 298
11. FI Malik, JJ Hartman, KA Elias et al. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure Science 331 2011 1439 1443
12. BP Morgan, A Muci, PP Lu et al. Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac myosin ACS Med Chem Lett 1 2010 472 477
13. YT Shen, FI Malik, X Zhao et al. Improvement of cardiac function by a cardiac myosin activator in conscious dogs with systolic heart failure Circ Heart Fail 3 2010 522 527
14. BP Smith, FR Vandenhende, KA DeSante et al. Confidence interval criteria for assessment of dose proportionality Pharm Res 17 2000 1278 1283
15. L Thomas, M Hoy, K Byth, NB Schiller The left atrial function index: a rhythm independent marker of atrial function Eur J Echocardiogr 9 2008 356 362 (Pubitemid 351670677)
16. T Pollard, WC Earnshaw Cell biology 2nd edn. 2008 Saunders/Elsevier Philadelphia, PA 705 725
17. T Suzuki, BM Palmer, J James et al. Effects of cardiac myosin isoform variation on myofilament function and crossbridge kinetics in transgenic rabbits Circ Heart Fail 2 2009 334 341
18. RP Lewis, SE Rittogers, WF Froester, H Boudoulas A critical review of the systolic time intervals Circulation 56 1977 146 158 (Pubitemid 8247470)
19. AM Weissler, WS Harris, CD Schoenfeld Systolic time intervals in heart failure in man Circulation 37 1968 149 159
20. B Moyers, M Shapiro, GM Marcus et al. Performance of phonoelectrocardiographic left ventricular systolic time intervals and B-type natriuretic peptide levels in the diagnosis of left ventricular dysfunction Ann Noninvasive Electrocardiol 12 2007 89 97 (Pubitemid 46889914)
21. P Carvalho, RP Paiva, R Couceiro et al. Assessing systolic time-intervals from heart sound: a feasibility study Conf Proc IEEE Eng Med Biol Soc 2009 2009 3124 3128
22. JD Thomas, ZB Popovic Assessment of left ventricular function by cardiac ultrasound J Am Coll Cardiol 48 2006 2012 2025 (Pubitemid 44738435)
23. JGF Cleland, JR Teerlink, R Senior et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial Lancet 378 2011 676 683